{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T01:07:03Z","timestamp":1788570423292,"version":"build-2803163510"},"reference-count":23,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100009104","name":"Department of Health Research, India","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009104","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.clinthera.2023.04.004","type":"journal-article","created":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T22:34:57Z","timestamp":1682116497000},"page":"458-465","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Cost-utility of Ranolazine for Chronic Stable Angina Pectoris: Systematic Review and Meta-analysis"],"prefix":"10.1016","volume":"45","author":[{"given":"Lavanya","family":"Ayyasamy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0856-767X","authenticated-orcid":false,"given":"Bhavani Shankara","family":"Bagepally","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2023.04.004_bib0001","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1080\/13543784.2016.1254617","article-title":"Experimental and early investigational drugs for angina pectoris","volume":"25","author":"Elgendy","year":"2016","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.clinthera.2023.04.004_bib0002","article-title":"Global epidemiology of ischemic heart disease: results from the Global Burden of Disease Study","volume":"12","author":"Khan","year":"2020","journal-title":"Cureus"},{"issue":"11 Suppl","key":"10.1016\/j.clinthera.2023.04.004_bib0003","first-page":"S347","article-title":"A systematic review of the economic burden of chronic angina","volume":"10","author":"Reynolds","year":"2004","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.clinthera.2023.04.004_bib0004","unstructured":"STABLE ANGINA Produced by the National Clinical Guidelines Centre. The National Clinical Guidelines Centre; 2011."},{"key":"10.1016\/j.clinthera.2023.04.004_bib0005","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1093\/eurheartj\/eht296","article-title":"2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology","volume":"34","author":"Montalescot","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clinthera.2023.04.004_bib0006","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1001\/jama.291.3.309","article-title":"Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial","volume":"291","author":"Chaitman","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2023.04.004_bib0007","first-page":"148","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement","volume":"20","author":"Moher","year":"2016","journal-title":"Revista Espanola de Nutricion Humana y Dietetica"},{"key":"10.1016\/j.clinthera.2023.04.004_bib0008","unstructured":"WebPlotDigitizer. Extract data from plots, images, and maps. Accessed August 23, 2022. https:\/\/automeris.io\/WebPlotDigitizer\/"},{"key":"10.1016\/j.clinthera.2023.04.004_bib0009","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1586\/14737167.2015.1103185","article-title":"Risk of bias in model-based economic evaluations: the ECOBIAS checklist","volume":"16","author":"Adarkwah","year":"2016","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"10.1016\/j.clinthera.2023.04.004_bib0010","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1016\/j.jval.2019.09.2750","article-title":"Cost utility of sodium-glucose cotransporter 2 inhibitors in the treatment of metformin monotherapy failed type 2 diabetes patients: a systematic review and meta-analysis","volume":"22","author":"Bagepally","year":"2019","journal-title":"Value Health"},{"key":"10.1016\/j.clinthera.2023.04.004_bib0011","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s00228-021-03242-6","article-title":"Incremental net benefit of lipid-lowering therapy with PCSK9 inhibitors: a systematic review and meta-analysis of cost-utility studies","volume":"78","author":"Bagepally","year":"2021","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2023.04.004_bib0012","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12913-022-07595-1","article-title":"Meta-analysis of economic evaluation studies: data harmonisation and methodological issues","volume":"22","author":"Bagepally","year":"2022","journal-title":"BMC Health Services Res"},{"key":"10.1016\/j.clinthera.2023.04.004_bib0013","unstructured":"World Bank Country and Lending Groups\u2013World Bank Data Help Desk. Accessed August 23, 2022. https:\/\/datahelpdesk.worldbank.org\/knowledgebase\/articles\/906519-world-bank-country-and-lending-groups"},{"key":"10.1016\/j.clinthera.2023.04.004_bib0014","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"1558","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"key":"10.1016\/j.clinthera.2023.04.004_bib0015","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"10.1016\/j.clinthera.2023.04.004_bib0016","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2015-008861","article-title":"Ranolazine for the treatment of chronic stable angina: a cost-effectiveness analysis from the UK perspective","volume":"5","author":"Coleman","year":"2015","journal-title":"BMJ Open"},{"key":"10.1016\/j.clinthera.2023.04.004_bib0017","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ijcard.2018.09.060","article-title":"Ranolazine in patients with type 2 diabetes and chronic angina: a cost-effectiveness analysis and assessment of health-related quality-of-life","volume":"273","author":"Nguyen","year":"2018","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.clinthera.2023.04.004_bib0018","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/BF03320519","article-title":"Una valutazione economica di ranolazina add-on nel trattamento dell'angina stabile cronica","volume":"11","author":"Lucioni","year":"2009","journal-title":"PharmacoEconomics Italian Research Articles"},{"key":"10.1016\/j.clinthera.2023.04.004_bib0019","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.amjcard.2014.01.407","article-title":"Cost-effectiveness of ranolazine added to standard-of-care treatment in patients with chronic stable angina pectoris","volume":"113","author":"Kohn","year":"2014","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.clinthera.2023.04.004_bib0020","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/s10198-013-0534-8","article-title":"Cost-utility of ranolazine for the symptomatic treatment of patients with chronic angina pectoris in Spain","volume":"15","author":"Hidalgo-Vega","year":"2014","journal-title":"Eur J Health Economics"},{"key":"10.1016\/j.clinthera.2023.04.004_bib0021","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12913-015-1228-y","article-title":"Ranolazine for the symptomatic treatment of patients with chronic angina pectoris in Greece: a cost-utility study","volume":"15","author":"Kourlaba","year":"2015","journal-title":"BMC Health Services Res"},{"key":"10.1016\/j.clinthera.2023.04.004_bib0022","first-page":"475","article-title":"Clinical and economic assessment of the use of ranolazine in the health care system of the Republic of Belarus","volume":"11","author":"Kozhanova","year":"2019","journal-title":"Kardiologija v Belarusi"},{"key":"10.1016\/j.clinthera.2023.04.004_bib0023","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ijcard.2016.02.140","article-title":"A literature review to evaluate the economic value of ranolazine for the symptomatic treatment of chronic angina pectoris","volume":"211","author":"Vellopoulou","year":"2016","journal-title":"Int J Cardiol"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291823001315?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291823001315?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T19:05:48Z","timestamp":1719342348000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291823001315"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S0149291823001315"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2023.04.004","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-utility of Ranolazine for Chronic Stable Angina Pectoris: Systematic Review and Meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2023.04.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}